MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Bio Blast Pharma Ltd Company Profile (NASDAQ:ORPN)

Consensus Ratings for Bio Blast Pharma Ltd (NASDAQ:ORPN) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.75 (1,322.16% upside)

Analysts' Ratings History for Bio Blast Pharma Ltd (NASDAQ:ORPN)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Roth CapitalReiterated RatingBuy$23.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016Rodman & RenshawLower Price TargetBuy$25.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016HC WainwrightInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/27/2015OppenheimerReiterated RatingOutperform$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Bio Blast Pharma Ltd (NASDAQ:ORPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/19/2016        
5/25/2016Q1($0.29)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($0.25)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2015Q3($0.29)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/21/2015Q2($0.28)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/19/2015Q115($0.25)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2015Q414($0.16)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/21/2014($0.09)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/29/2014Q214($0.09)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Bio Blast Pharma Ltd (NASDAQ:ORPN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.33)($0.26)($0.30)
Q2 20161($0.33)($0.33)($0.33)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)
Dividend History for Bio Blast Pharma Ltd (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Bio Blast Pharma Ltd (NASDAQ:ORPN)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Bio Blast Pharma Ltd (NASDAQ:ORPN)
DateHeadline
06/27/16 05:39 PMStrong Sell Calls Recommendations For Bio Blast Pharma Ltd. (NASDAQ:ORPN) At 0 - Investor Newswire
06/27/16 09:50 AMAre Analysts Bearish Bio Blast Pharma Ltd (NASDAQ:ORPN) After Last Week? - Engelwood Daily
06/24/16 08:15 AMRetrophin (RTRX) RE-024 Positive in Physician-Initiated Study
06/23/16 07:25 AMArQule (ARQL) Shows Strength: Stock Adds 8% in Session -
06/20/16 05:30 PMStrong Buy Calls Count For Bio Blast Pharma Ltd. (NASDAQ:ORPN) At 2 - Investor Newswire
06/20/16 07:17 AMThis Weeks Broker Views For Bio Blast Pharma Ltd. (ORPN) - Fiscal Standard
06/16/16 09:52 AMBio Blast Pharma Ltd. (ORPN) Current Analyst Ratings - Fiscal Standard
06/16/16 07:31 AMShould You Get Rid of Valeant Pharmaceuticals (VRX) Now? -
06/14/16 05:24 PMResolute Forest Products Inc. (NYSE:RFP) plummeted -6.48%: Bio Blast Pharma Ltd. (NASDAQ:ORPN), Avnet, Inc ... - KC Register
06/13/16 05:15 PMZafgen (ZFGN) Presents Favorable New Data on Beloranib
06/13/16 08:38 AMNew Strong Buy Stocks for June 13th
06/09/16 08:39 AMBioBlast Pharma (ORPN) Plans Trehalose IV Phase 2b in OPMD; Will Evaluate in Other Orphan Diseases - StreetInsider.com
06/09/16 05:02 AM6:02 am Bio Blast Pharma announces plans to initiate a Phase 2b trial with trehalose IV solution in OPMD during the second half of 2016, CFO to leave the co, CEO Colin Foster leaves position but remains on the Board, Executive Chairman Fred -
06/09/16 05:00 AMBioblast Pharma Updates Corporate Plans - [GlobeNewswire] - Trehalose Phase 2 b Trial in Oculopharyngeal Muscular Dystrophy On Track to Commence During the Second Half of 2016. Focus On Trehalose As a Potential Platform. Corporate Restructuring and Management Changes: ...
06/06/16 09:22 AMNokia Corporation (ADR) (NYSE:NOK) increased 0.53%: Bio Blast Pharma Ltd. (NASDAQ:ORPN), IdaCorp, Inc. (NYSE ... - KC Register
06/06/16 09:22 AMMakeMyTrip Limited (NASDAQ:MMYT) decreased -2.35%: Bio Blast Pharma Ltd. (NASDAQ:ORPN), Pacira ... - KC Register
06/02/16 10:18 AM5 Stocks Under $5 With Potential (SIRI,GRPN,KTOS) -
05/31/16 12:17 AMAnalysts Expect Bio Blast Pharma Ltd (NASDAQ:ORPN) to Post ($0.29) EPS - Let Me Know About This - Analysts Expect Bio Blast Pharma Ltd (NASDAQ:ORPN) to Post ($0.29) EPSLet Me Know About ThisBio Blast Pharma logo Shares of Bio Blast Pharma Ltd (NASDAQ:ORPN) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research ...Next Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN)Share Trading NewsHow Many Bio Blast Pharma Ltd (NASDAQ:ORPN)'s Analysts Are Bearish?The PostBio Blast Pharma Ltd. (NASDAQ:ORPN) Quarterly EPS From Continuing Operations Stands At $-0.3175Equities FocusFranklin Independentall 5 news articles »
05/30/16 05:46 PMNext Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN) - Share Trading News - Next Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN)Share Trading NewsBio Blast Pharma Ltd. has a 50 day moving average of 2.16 and a 200 day moving average of 3.11. The stock's market capitalization is 28.18M, it has a 52-week low of 1.65 and a 52-week high of 8.50. The share price of the company (ORPN) was down ...How Many Bio Blast Pharma Ltd (NASDAQ:ORPN)'s Analysts Are Bearish?The PostBio Blast Pharma Ltd. (NASDAQ:ORPN) Quarterly EPS From Continuing Operations Stands At $-0.3175Equities FocusIs it Time to Cash in Profits on Bio Blast Pharma Ltd. (NASDAQ:ORPN)Franklin Independentall 5 news articles »
05/30/16 05:46 PMNext Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN) - Share Trading News - Next Weeks Broker Price Targets For Bio Blast Pharma Ltd. (ORPN)Share Trading NewsBio Blast Pharma Ltd. has a 50 day moving average of 2.16 and a 200 day moving average of 3.11. The stock's market capitalization is 28.18M, it has a 52-week low of 1.65 and a 52-week high of 8.50. The share price of the company (ORPN) was down ...How Many Bio Blast Pharma Ltd (NASDAQ:ORPN)'s Analysts Are Bearish?The PostBio Blast Pharma Ltd. (NASDAQ:ORPN) Quarterly EPS From Continuing Operations Stands At $-0.3175Equities FocusIs it Time to Cash in Profits on Bio Blast Pharma Ltd. (NASDAQ:ORPN)Franklin Independentall 5 news articles »
05/25/16 10:56 AMBio Blast posts 1Q loss -
05/25/16 10:56 AMBio Blast posts 1Q loss -
05/25/16 07:00 AMBioblast Pharma Reports First Quarter 2016 Financial Results - [GlobeNewswire] - NEW HAVEN, Conn., May 25, 2016-- Bioblast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31, 2016.. “During ...
05/25/16 07:00 AMBioblast Pharma Reports First Quarter 2016 Financial Results - [GlobeNewswire] - NEW HAVEN, Conn., May 25, 2016-- Bioblast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31, 2016.. “During ...
04/15/16 08:22 AMBio Blast Gains 9%, Company Will Present Final Phase 2 Trial Data At Industry Conference - Shares of Bio Blast Pharma Ltd (NASDAQ: ORPN) were trading higher by more than 9 percent early Friday morning after the company announced it will present final data from a Phase 2 clinical study at the American Academy of Neurology (AAN) 2016 ...Full story available on Benzinga.com
04/14/16 03:05 PMBioBlast Pharma to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose in Oculopharyngeal Muscular Dystrophy at the American Academy of Neurology (AAN) 2016 Annual Meeting - [GlobeNewswire] - NEW HAVEN, Conn., April 14, 2016-- BioBlast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive final results from its HOPEMD Phase 2 ...
04/14/16 03:05 PMBioBlast Pharma to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose in Oculopharyngeal Muscular Dystrophy at the American Academy of Neurology (AAN) 2016 Annual Meeting - [GlobeNewswire] - NEW HAVEN, Conn., April 14, 2016-- BioBlast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive final results from its HOPEMD Phase 2 ...
03/20/16 09:35 AM4 Key Biopharma Movers of the Past Week -
03/20/16 09:35 AM4 Key Biopharma Movers of the Past Week -
03/17/16 07:15 AMBio Blast Pharma (ORPN) in Focus: Stock Moves Up 54.5% -
03/17/16 07:15 AMBio Blast Pharma (ORPN) in Focus: Stock Moves Up 54.5% -
03/17/16 06:00 AMBioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering - [GlobeNewswire] - NEW HAVEN, Conn., March 17, 2016-- BioBlast Pharma Ltd. announced that it has entered into definitive securities purchase agreements with two healthcare focused institutional investors providing for the ...
03/17/16 06:00 AMBioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering - [GlobeNewswire] - NEW HAVEN, Conn., March 17, 2016-- BioBlast Pharma Ltd. announced that it has entered into definitive securities purchase agreements with two healthcare focused institutional investors providing for the ...
03/16/16 02:18 PMWhy Oracle (ORCL), Celator Pharma (CPXX), Peabody Energy (BTU) and Others Are Trending Today -
03/16/16 02:18 PMWhy Oracle (ORCL), Celator Pharma (CPXX), Peabody Energy (BTU) and Others Are Trending Today -
03/16/16 09:45 AMBio Blast Pharma Explodes on Positive Results -
03/16/16 09:45 AMBio Blast Pharma Explodes on Positive Results -
03/14/16 11:12 AMBio Blast Pharma (ORPN) Working in Unchartered Territory - Equities.com - Equities.comBio Blast Pharma (ORPN) Working in Unchartered TerritoryEquities.comHowever, Bio Blast Pharma Ltd. (ORPN) is working to change that by providing meaningful drugs and therapies for patients with rare diseases. The Tel Aviv-based Bio Blast focuses on rare neuromuscular and mitochondrial diseases with vast unmet ...
03/10/16 07:00 AMBioBlast Pharma to Present Corporate Overview at the 28th Annual ROTH Conference - [GlobeNewswire] - NEW HAVEN, Conn., March 10, 2016-- BioBlast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and CEO, will provide a corporate overview ...
02/23/16 03:05 PMBioBlast Pharma Reports Fourth Quarter and Full Year 2015 Financial Results - [GlobeNewswire] - NEW HAVEN, Conn., Feb. 23, 2016-- BioBlast Pharma Ltd., a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the fourth quarter and fiscal year ended December ...
02/16/16 01:28 PMNew Price Targets On Bio Blast Pharma Ltd. (ORPN) - Risers & Fallers - New Price Targets On Bio Blast Pharma Ltd. (ORPN)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Bio Blast Pharma Ltd. (ORPN). The latest broker reports which are currently outstanding on Tuesday 16th of February state 0 analysts have a rating of “strong buy”, 2 ...
02/15/16 12:43 PMEarnings Per Share for Bio Blast Pharma Ltd (ORPN) Projected to Decrease - WallStreet.org - Earnings Per Share for Bio Blast Pharma Ltd (ORPN) Projected to DecreaseWallStreet.orgWall Street await Bio Blast Pharma Ltd (NASDAQ:ORPN) to release earnings on February, 16. Analysts forecast EPS of $-0.26, down exactly $0.04 or 18.18% from 2014's $-0.22 EPS. After releasing $-0.25 EPS for the previous quarter, Bio Blast Pharma Ltd's ...
02/12/16 07:48 AMShould You Sell Bio Blast Pharma (ORPN) Before Earnings? -
01/30/16 11:20 AMBio Blast Pharma Ltd (NASDAQ:ORPN) Stock: H.C. Wainwright Initiates Coverage with Buy Outlook - OctaFinance.com - Bio Blast Pharma Ltd (NASDAQ:ORPN) Stock: H.C. Wainwright Initiates Coverage with Buy OutlookOctaFinance.comIn a report revealed today, H.C. Wainwright analysts started Bio Blast Pharma Ltd (NASDAQ:ORPN) coverage with Buy rating, and a $25.00 target price. The initiation is well-received by investors, as NASDAQ:ORPN is at the moment trading 4.63% higher at ...
01/28/16 06:07 AMCoverage initiated on Bio Blast Pharma by Rodman & Renshaw -
11/17/15 07:07 AMBio Blast reports 3Q loss -
11/16/15 07:45 AMBioBlast Pharma Strengthens Leadership Team and Announces Key Organizational Changes - [at noodls] - Significant Evolution of Senior Leadership Team in 2015 Co-Founders Transition Company to Globally-Experienced Executives NEW HAVEN, Conn., Nov. 16, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), ...
11/09/15 07:30 AMCellect Biomed Announces Key Leadership Changes - [GlobeNewswire] - TEL-AVIV, Israel -- Cellect Biomed Ltd. ("Cellect" or the "Company"), a developer of innovative technology which enables the functional selection of stem cells, announced additions ...
11/09/15 07:06 AMBioBlast Pharma Announces Website Availability of Webcast Related to Key Opinion Leader Meeting in Oculopharyngeal Muscular Dystrophy (OPMD) - [at noodls] - NEW HAVEN, Conn., Nov. 9, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare genetic ...
10/27/15 12:26 PMA Look at 5 Major Stock Market Gainers and the Drivers Behind Their Sharp Uptrend -
About Bio Blast Pharma Ltd

Bio Blast Pharma Ltd logoBio Blast Pharma Ltd. (BioBlast) is a development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The Company is advancing its Cabaletta platform product candidates through clinical development and advancing its other product candidates, BB-FA, BB-OTC, and BBrm1, as well as its other early stage research projects, through preclinical development. The Company's three principal product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform. The Company is developing Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD); spinocerebellar ataxia type 3 (SCA3), and Spinobulbar Muscular Atrophy (SBMA). It is conducting preclinical studies of BBrm1 for the treatment of Spinal Muscular Atrophy (SMA).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ORPN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.62
  • 50 Day Moving Average: $1.90
  • 200 Day Moving Average: $2.69
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $23.73M
  • Current Quarter EPS Consensus Estimate: $-1.17 EPS
Additional Links:
Bio Blast Pharma Ltd (NASDAQ:ORPN) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha